Editorial note: This is an independent review by the TotalCareMedical.com editorial team. Novi is a telehealth platform operated by Novi International LLC. The compounded medications referenced — semaglutide and tirzepatide — are not FDA-approved finished drugs. Nothing in this review constitutes medical advice. GLP-1 medications are prescription only and must be evaluated by a licensed clinician for each individual.
Most reviews of compounded GLP-1 telehealth platforms read like they were written six months ago. That used to be fine. Two days ago, it stopped being fine.
On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory mechanism that has allowed large-scale outsourcing facilities to compound these GLP-1 medications during and after the 2022–2024 shortage period. Public comments are open through June 29, 2026. If finalized, the rule reshapes the compounded GLP-1 telehealth landscape that platforms like Novi operate inside.
This review reads Novi inside that new context. What the platform offers, what it costs, what happens when you cancel, what's clear in the terms of service and what isn't, and which questions the FDA proposal makes more important to ask before a 3-month commitment.
What Novi Is, and Who Operates It
Novi (joinnovi.com) is a direct-to-consumer telehealth weight management platform. It is operated by Novi International LLC, with a Wyoming registered address (30 N Gould St Ste R, Sheridan, WY 82801) and a Dallas, Texas operational address (4131 N Central Expy #900, Dallas, TX 75204). The platform's terms reference both “Novi International LLC” and “Novi Health LLC” — the latter appears in the binding arbitration section as the contracting party for disputes. Texas law governs the terms; arbitration runs through JAMS in Dallas County.
The model is straightforward. A user completes an online medical intake quiz, a US-licensed clinician reviews the submission and (when needed) conducts a virtual consultation, and — if treatment is determined to be medically appropriate — the user receives a prescription that ships from a licensed US pharmacy.
The marketed medications are compounded semaglutide (described by Novi as “same active ingredient as Ozempic® and Wegovy®,” from $174) and compounded tirzepatide (“same active ingredient as Mounjaro® and Zepbound®,” from $283). The platform offers free 2-day shipping and includes provider check-ins, dose adjustments, and coaching at no additional charge per its published program description. The monthly subscription fee includes a $20 independent physician consultation fee paid to an independent medical group.
Novi's published clinical team includes Daniel Funsch, MD (American Board of Emergency Medicine), Michael Wasef, MD (American Board of Internal Medicine), Takashi Nakamura, MD (American Board of Emergency Medicine), and several nurse practitioners — Kimberli Hastings, NP, Kristine Clements, NP, and Theresa Vergara, NP. The platform states services are limited to US residents 18 and older, and that prescribing is subject to state telehealth laws.
The April 30, 2026 FDA Proposal — and Why It Matters Here
The FDA's proposed rule, announced via a press release on April 30, 2026 and a Federal Register notice on May 1, would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. In plain terms: large-scale 503B outsourcing facilities would be barred from compounding these three drugs from bulk active pharmaceutical ingredient — closing a pathway that opened during the 2022 shortage and that powered much of the compounded-GLP-1 telehealth industry.
The mechanics matter. There are two compounding pathways. 503A pharmacies are state-licensed pharmacies that compound patient-specific prescriptions — one prescription, one patient, often customized. The FDA's April 30 proposal does not directly target 503A pharmacies; that pathway operates under a separate legal framework. 503B outsourcing facilities are larger compounders that produce in batch quantity and historically relied on the shortage list or the 503B bulks list as their legal basis. With both shortages now resolved (tirzepatide in December 2024, semaglutide in February 2025) and the 503B bulks listing now formally proposed for exclusion, the 503B pathway for these drugs is being closed.
Several major telehealth players have already announced shifts away from compounded GLP-1s. Patient safety reporting cited by the FDA includes more than 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide as of early 2025, with concerns including dosing errors and counterfeit supply.
For prospective Novi patients, the practical question is direct: which compounding pathway does Novi's pharmacy network operate under? Novi's published terms describe sourcing from “trusted, licensed U.S. pharmacies” but do not name the specific pharmacy partners or specify 503A versus 503B. That's a question worth asking customer support before signing the 3-month commitment, particularly given the regulatory direction.
The Pricing — and the 3-Month Commitment
Novi's headline pricing is $174/month for compounded semaglutide and $283/month for compounded tirzepatide. The “from” qualifier is in the marketing — actual pricing depends on dose tier and any pharmacy fees. Brand-name medications are not the platform's primary offering; the marketing explicitly positions the compounded options as the affordable alternative for cash-pay patients.
The detail that doesn't appear in the marketing copy and does appear in the published terms of service: subscription-based products on Novi require a 3-month minimum commitment. Per the terms, the first month's fee plus the next two months' fees (three months total) are charged at the time of purchase and are non-refundable, unless a provider determines treatment is not medically appropriate before any prescription is dispensed.
To cancel, the user must submit cancellation at least 15 days before the next monthly processing date — and only after the 3-month commitment period has concluded — to stop further charges. Once a prescription is dispensed or shipped, it can't be returned or refunded under any condition.
That structure is not unique to Novi. Several compounded-GLP-1 telehealth platforms use 3-month commitments. It's worth understanding before paying. A more granular pricing breakdown — including what's covered in the “all-in” monthly fee and what isn't — is in our companion Novi cost analysis.
What the Underlying Medications Do
The active ingredients Novi prescribes — semaglutide and tirzepatide — are GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide). Both classes work by mimicking incretin hormones the gut releases in response to food. The downstream effects include slowed gastric emptying, reduced appetite signaling, and improved glycemic control.
The peer-reviewed efficacy data for these molecules — at FDA-approved doses, in FDA-approved finished drug products — is substantial. Phase 3 trials of brand-name semaglutide 2.4 mg (the STEP program) have reported average body weight reductions in the range of approximately 14.9% over 68 weeks in adults without type 2 diabetes. Phase 3 trials of brand-name tirzepatide 15 mg (the SURMOUNT program) have reported reductions in the range of approximately 20.9% over 72 weeks in similar populations. A 2026 systematic review aggregating 22 randomized controlled trials with 41,757 individuals confirmed semaglutide 2.4 mg and tirzepatide at 5/10/15 mg doses as consistently effective for weight loss in patients with and without diabetes.
Three caveats that matter for any compounded-GLP-1 telehealth review. First, those trial outcomes were generated using FDA-approved finished products at specific doses with specific titration protocols — not using compounded versions. Second, individual results vary substantially. Third, the effect persists during treatment; discontinuation without sustained behavioral change is associated with weight regain in the published literature. Novi's marketing claim of “lose up to 24% of your body weight” is a marketing claim that exceeds the upper end of typical brand-name trial reporting and is not supported by published Novi-specific trial data. Treat it accordingly.
The Honest-Broker Read on the Clinical Process
Novi's published intake process — online questionnaire, clinician review, virtual visit when indicated, prescription when medically appropriate, ongoing provider access — is consistent with how most reputable compounded-GLP-1 telehealth platforms operate. The platform states it screens for eligibility based on standard medical criteria (BMI, comorbidities, contraindications), and that providers retain authority to deny treatment for misuse risk.
What's worth verifying with any compounded-GLP-1 telehealth platform — Novi included — before paying:
Whether the prescribing pathway is 503A or 503B, given the regulatory direction. The named pharmacy partners (compare against the FDA's registered outsourcing facility list at fda.gov). Whether certificates of analysis are available on request for sterility, endotoxin, and potency testing. Whether the medication is semaglutide free base or sodium versus semaglutide acetate (acetate forms have been associated with quality concerns and are not the form used in FDA-approved finished products). The full schedule of follow-ups and how dose titration is handled. The exact terms of the 3-month commitment relative to your state's telehealth and consumer protection laws.
Most of these are answerable by emailing support@joinnovi.com before committing. We discuss the compounded-versus-brand distinction in regulatory depth in our Novi compounded vs brand analysis.
What's Missing From Most Novi Reviews
Most third-party Novi reviews on the open web pre-date the April 30, 2026 FDA proposal entirely. They treat compounded GLP-1 access as a stable category. They quote the marketing testimonial figures (“Lost 52 lbs in 5 months”) as if those were verified outcomes. They don't address the 3-month commitment in the terms of service. And they don't ask about the pharmacy pathway.
This isn't unique to Novi. The same gap exists across reviews of SynergyRx, TeleHealth Med, and the broader compounded-GLP-1 category. The next 60–90 days will sort the platforms that adapt their sourcing from those that don't. A consumer evaluating any of these platforms today is making a 3-month commitment into a regulatory environment that's actively changing.
Side Effects, Safety Screening, and What to Expect
GLP-1 receptor agonists carry a documented side effect profile — primarily gastrointestinal. The most commonly reported in clinical trials and post-marketing data: nausea (14%–28% in published trials), vomiting (6%–12%), diarrhea (8%–20%), constipation, and decreased appetite. Most are most pronounced during dose titration and tend to attenuate as the body adjusts. Rarer but more serious risks include pancreatitis, gallbladder issues, and contraindications around personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and certain pancreatic conditions.
Novi's intake process is designed to screen for these contraindications. The platform's documented telehealth consent acknowledges that virtual evaluation cannot substitute for in-person physical examination in all cases, and that some patients may need additional in-person clinical workup before treatment is appropriate. We cover the side effect profile and Novi's specific cancellation and refund mechanics in detail in our Novi side effects and cancellation policy review.
Who Novi Likely Fits — and Who It Doesn't
Novi may be a reasonable consideration for adults who meet standard prescribing criteria for GLP-1 weight management (BMI ≥30, or ≥27 with at least one weight-related comorbidity), who are seeking cash-pay access at compounded-medication price points, who can comfortably absorb a 3-month commitment regardless of how they respond to the medication, and who are willing to ask the regulatory pathway questions before paying.
Novi is not a fit for individuals with contraindications to GLP-1 therapy, those who require insurance coverage for brand-name medications, those who would need to discontinue at month one or two, those who require in-person clinical workup, or those who are uncomfortable with the compounded-medication category at all. The April 30, 2026 FDA proposal is an explicit signal that this category is contracting at the 503B level.
For a platform-by-platform comparison against the other two compounded-GLP-1 telehealth services we've reviewed, see our Novi vs SynergyRx vs TeleHealth Med comparison.
Bottom Line
Novi is a functioning compounded-GLP-1 telehealth platform with transparent published terms, a named clinical team, and competitive cash-pay pricing. The marketing is more aggressive than the documentation supports — the “up to 24% body weight” line and the prominent testimonial figures should be read as marketing, not as outcome data — but the underlying program structure is consistent with the category.
The real diligence question is not whether Novi works as advertised. It's whether the compounded-GLP-1 pathway Novi relies on continues to function as the FDA finalizes its April 30, 2026 proposal over the next several months. That answer depends on Novi's specific pharmacy network and whether it operates under 503A (still permitted), 503B (now under formal regulatory threat), or a combination. Any prospective patient considering a 3-month financial commitment is owed a straight answer to that question before paying.
Ask before you sign. The platforms that answer cleanly are the ones built to last past June 29, 2026.